Annual Report 2022
Department of Musculoskeletal Oncology
Fumihiko Nakatani, Jun Sugaya
Introduction
The Department of Musculoskeletal Oncology of NCCHE is a team consisting of two orthopedic surgeons that started in 2021. We strive to provide expert interdisciplinary care for benign and malignant bone and soft tissue tumors and tumor-like conditions. Currently, we perform a variety of bone and soft tissue tumor surgeries with the aid of other department staff, including plastic surgery, thoracic surgery and colorectal surgery. Chemotherapy and radiotherapy for malignant musculoskeletal tumors are currently conducted in the Departments of Medical Oncology and Radiotherapy, respectively.
The Team and What We Do
Our outpatient service is generally open three days a week (Mondays, Thursdays, and Fridays) for patients with various musculoskeletal tumors. We also manage patients who suffer from bone metastases and other orthopedic diseases, and consult with other cancer specialists on a daily basis. To provide prosthetic and orthotic care for our patients, a special outpatient service is available on Fridays. A constant number of over four patients are hospitalized for operations or radiation therapy. One or two major operations are routinely performed every week. In 2022, as shown in Table 1, 75 operations were performed. A total of ten reconstructive operations were conducted in collaboration with plastic surgeons to achieve adequate soft tissue coverage after the resection of malignant tumors of the trunk or limb-salvage operations for sarcomas of the extremities. With regard to the patients’ postoperative course, we have been collaborating with a physical therapist to rehabilitate the musculoskeletal system in cancer-bearing patients.
Table 1. Type of surgical procedure (2022)
Research Activities
We have been attending multi-institutional study groups including the Japan Clinical Oncology Group (JCOG) and the Japan Musculoskeletal Oncology Group (JMOG) to produce novel evidence for rare musculoskeletal tumors. We are also engaged in developing a system for the early detection of bone metastasis and spinal canal invasion by metastatic tumors using a subtraction method with CT-based images in collaboration with radiologists.
Clinical Trials
1. A multi-institutional randomized phase II clinical trial of second line chemotherapy for advanced soft tissue sarcoma (JCOG1802) since 2019
2. A multi-institutional randomized phase III clinical trial of (neo)adjuvant chemotherapy for soft tissue sarcoma (JCOG 2102) since 2022
Education
We have been engaging in several educational lectures for the medical staff to promote specific care regarding musculoskeletal oncology. We also provide some instructive lectures for the medical staff in the community.
Future Prospects
Our division continues to focus on the development of novel therapeutic tools for patients with bone and soft tissue tumors in collaboration with other clinical divisions and research institutes.
List of papers published in 2022
Journal
1. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sugaya J, Kobayashi E, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. Human cell, 35:2011-2019, 2022
2. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sugaya J, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma. Human cell, 35:1290-1297, 2022
3. Toki S, Sone M, Yoshida A, Nishisho T, Gokita T, Kobayashi E, Nakatani F, Chuman H, Sugawara S, Arai Y, Kawai A. Image-guided core needle biopsy for musculoskeletal lesions. Journal of orthopaedic science, 27:448-455, 2022
4. Nakagawa M, Sekimizu M, Endo M, Kobayashi E, Iwata S, Fukushima S, Yoshida A, Kitabayashi I, Ichikawa H, Kawai A, Nakatani F. Prognostic impact of IDH mutations in chondrosarcoma. Journal of orthopaedic science, 27:1315-1322, 2022
5. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Iwata S, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Human cell, 35:936-943, 2022
6. Ogiwara Y, Nakagawa M, Nakatani F, Uemura Y, Zhang R, Kudo-Saito C. Blocking FSTL1 boosts NK immunity in treatment of osteosarcoma. Cancer letters, 537:215690, 2022
7. Nakagawa M, Yamaguchi M, Endo M, Machida Y, Hattori A, Tanzawa F, Tsutsumi S, Kitabayashi I, Kawai A, Nakatani F. Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma. Journal of bone oncology, 34:100430, 2022
8. Hidaka N, Koga M, Kimura S, Hoshino Y, Kato H, Kinoshita Y, Makita N, Nangaku M, Horiguchi K, Furukawa Y, Ohnaka K, Inagaki K, Nakagawa A, Suzuki A, Takeuchi Y, Fukumoto S, Nakatani F, Ito N. Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia: Outcome of a Retrospective Surveillance. Journal of bone and mineral research, 37:1479-1488, 2022